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patients. A typical PCU admits patients in the ﬁnal phase of life. A high quality of 
care by a multi disciplinary team (including nurses, physicians, psychologists, music 
therapy, physiotherapy and others) results in substantial costs (recent survey in 
German PCUs: on average ~a400/day). The average length of stay is in the range of 
11–15 days, the proportion of discharged patients varies between 40–70%, for the 
remaining patients the admission ends not unexpectedly with the death of the patients. 
The gain in utility close to death is difﬁcult to estimate, but even high assumptions 
(e.g. 0,5) result in costs for QALYs, which are unexpectedly high. Scenario 1: 14, 0.5, 
30, 0.5, 400, 192455 a; scenario 2: 14, 0.7,30, 0.5, 400, 172545 a; scenario 3: 14, 
0.5, 30, 0.3, 400, 320758 a; scenario 4: 10, 0.5, 30, 0.5, 400, 182500 a for length of 
stay (d), proportion surviving, survival after discharge (d), gain in utility, cost/day, 
resulting cost / QALY. People experiencing the sheer necessity of palliative care for a 
death with dignity may use these data as an argument against the QALY concept. 
Only by including longterm changes e.g. in the utility gain experienced by relatives 
(small gains over a long period in several persons, e.g. by avoiding pathological grief) 
the model results in costs/QALY which seem acceptable.
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OBJECTIVES: To evaluate treatment-related toxicities among patients with squamous 
cell carcinoma of the head and neck (SCCHN) treated in real-world clinical practices. 
METHODS: We used a population-based tumor registry at a large, US health system, 
to identify all cases of stage III or IV SCCHN diagnosed from 2000 to 2006. We 
identiﬁed the incidence/severity of acute and late toxicities associated with SCCHN 
treatment from detailed medical record reviews. Acute and late toxicities were evalu-
ated using CTCAE3 criteria and RTOG/EORTC late radiation morbidity scoring 
scheme, respectively. The incidence and severity of toxicities are presented by treat-
ments. Detailed analyses according to tumor stage and location, grade, and acute 
versus late events were examined. RESULTS: We identiﬁed 195 patients with SCCHN: 
A total of 104 patients (53%) received chemotherapy (chemo)  radiation therapy 
(RT); 87 (45%) received RT only; four patients (2%) received chemotherapy only or 
other/no treatment. Adverse Events of Interest (grade 2–4) by Treatment Received (N 
 191*): Gastrointestinal: 160 (83.8), 89 (85.6), 71 (81.6); Xerostomia: 61 (31.9), 41 
(39.4), 20 (23.0); Dysphagia: 70 (36.6), 44 (42.3), 26 (29.9); Dermatology: 91 (47.6), 
54 (51.9), 37 (42.5); Pulmonary: 74 (38.79), 41 (39.4), 33 (37.9); Aspiration pneu-
monia: 62 (32.5), 37 (35.6), 25 (28.7); Dehydration: 43 (22.5), 29 (27.9), 14 (16.1); 
Subcutaneous tissue: 30 (15.7), 18 (17.3), 12 (13.8); Infection: 29 (15.2), 21 (20.2), 
8 (9.2); Renal/Genitourinary: 19 (9.9), 14 (13.5), 5 (5.7); Auditory: 16 (8.4), 12 (11.5), 
4 (4.6); Bone: 4 (2.1), 3 (2.9), 1 (1.1) for Total n  191 n(%), ChemoRT n  104 
n(%), RT only n  87 n(%). Note: Four patients received chemotherapy only or 
other/no treatment. CONCLUSIONS: Treatment-related toxicity in patients with 
advanced SCCHN is common. The addition of chemotherapy to radiation is associ-
ated with increased risk treatment-related toxicities. These data provide real-world 
incidence rates of toxicity as observed in clinical practice.
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OBJECTIVES: The Dutch policy measure on expensive inpatient medicines aims to 
ensure accessibility by relieving ﬁnancial burden of hospitals. After three years, 
outcomes research inﬂuences decision-making on the continuation of additional 
funding. We explored the consequences of daily clinical practice variation for 
real-world pharmacoeconomics of bortezomib in relapsed or refractory multiple 
myeloma. METHODS: Our study included 139 multiple myeloma patients who 
progressed from ﬁrst line therapy and received bortezomib outside of an RCT. 
Detailed case reports were retrospectively collected from medical records in 38% of 
all Dutch hospitals. Treatment variation and combinations of bortezomib were 
explored until sixth line therapy. RESULTS: All patients had at least two treatment 
lines, 66% received third line, 41% fourth line, 14% ﬁfth line and 6% sixth line 
therapy. At least nine chemical agents were given in all lines as mono-therapy or in 
different combinations. No speciﬁc treatment order could be identiﬁed because of large 
variation in regimes and drug usage in different and reversed order. Moreover, guide-
lines have changed over the years and recommend earlier use of bortezomib; and 
lenalidomide, another very effective medicine, was increasingly used. In total, 72 
patients received bortezomib, 30% as mono-therapy and 70% as combination 
therapy. Bortezomib was most often combined with dexamethasone (60%), but com-
binations with ﬁve other drugs were seen. Clinical guidelines state that differences in 
patient circumstances require professional discretion; this results in extensive vari-
ability in daily practice. CONCLUSIONS: Compared to an RCT, outcomes research 
of bortezomib is complicated by extensive treatment variation in daily clinical practice. 
This suggests that a standard pharmacoeconomic model comparing two treatment 
arms is not sufﬁcient. Comprehensive modelling using different data sources is 
required to acquire a valid and precise (cost-) effectiveness measure of bortezomib in 
daily clinical practice.
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OBJECTIVES: Comparative effectiveness assessments require standardization of clini-
cal trial control arms to enable valid indirect comparisons. In order to inform guidelines 
on such adjustments, we provide insights on the Interferon-alpha-2a (IFN-A) control 
arm adjustment performed for comparing bevacizumab (BEV)  Interferon-alpha-2a 
(IFN-A) vs. sunitinib (SUN) in ﬁrst-line metastatic renal-cell cancer. METHODS: 
Adjustments were based on hazard ratios (HR) and median progression-free survival 
(PFS) time. Based on published phase-III trial investigator-assessed PFS (SUN vs. IFN-A 
HR 0.519; SUN PFS 10.8 months [m]; IFN-A 4.1m; BEVIFN-A vs. IFN-A HR 0.630; 
BEV PFS 10.2 m; IFN-A 5.4 m), indirect HRs were recalculated by adjusting IFN-A 
arms applying two scenarios: 1. IFN-A PFS of BEV  SUN IFN-A PFS (4.1 m); 
2. IFN-A PFS of SUN  BEV IFN-A PFS (5.4 m). Applying the cross-trial proportions 
of indirect HRs to direct HRs, the recalculated indirect HRs have been transferred to 
direct HR estimates (cross-trial rule of proportion approach). This approach was tested 
by adjusting the BEV trial IFN-A curve and recalculating the direct HR based on a 
Weibull model, applied to original phase III data. RESULTS: In scenario 1, the HR 
of SUN vs. IFN-A increased to 0.595; in scenario 2 the HR of BEVIFN-A decreased 
to 0.550. Indirect comparison results of SUN vs. BEVIFN-A where comparable for 
both scenarios (HR SUN vs. BEVIFN-A  0.945; CIs: 0.73–1.22; p-value  0.66). 
Testing scenario 2 based on a Weibull-function resulted in HR of BEV  IFN-A 
of 0.517. Applying an updated approach replicating the analysis results for scenario 
2 resulted in an indirect comparison HR of SUN vs. BEVIFN-A of 1.010 (CIs: 
0.79–1.30; p  0.94). CONCLUSIONS: As original trial data are often not accessible, 
using indirect HRs and adjusting them according to the method presented seems 
to be a practicable approach that could be performed based on published data.
PODIUM SESSION II: ECONOMIC EVALUATION AND REIMBURSEMENT 
DECISIONS I
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OBJECTIVES: The German HTA agency IQWiG published new guidelines on health-
economic evaluations for the statutory health care system. The goals of this pilot study 
commissioned by IQWiG were: 1) to apply the efﬁciency frontier (EF) approach 
to evaluate the cost-effectiveness of combination therapy with peginterferon plus 
 ribavirin (PegIFN  RBV) in patients with chronic hepatitis C (CHC); and 2) to assess 
the feasibility of the EF approach in this case example. METHODS: IQWiG’s EF 
approach assesses the cost-effectiveness of the new treatment (i.e., PegIFN  RBV) 
within the speciﬁc disease area (i.e., CHC) by comparing the new treatment’s incre-
mental cost-effectiveness ratio (ICER) to ICERs of established treatments. We used a 
lifetime Markov model to determine health outcomes and costs of all treatment 
options. Health outcomes included sustained virological response (SVR), lifetime risk 
of decompensated cirrhosis and quality-adjusted life years (QALY). Model parameters 
were derived from the published literature and German databases. We adopted the 
perspective of citizens insured through the statutory health insurance. We performed 
a budget impact analysis reporting annual incremental costs. RESULTS: The ICERs 
of PegIFN  RBV compared to interferon plus ribavirin (IFN  RBV) were EUR 
15,000 EUR/SVR avoided, EUR 42,000/decompensated cirrhosis avoided, and EUR 
4,000/QALY. These ICERs are substantially lower than those of the last segments 
of the respective EFs (i.e., ICER of IFN  RBV vs. IFN monotherapy) indicating cost-
effectiveness of PegIFN  RBV. The expected incremental annual budget ranged 
between 15 and 134 million EUR. The introduction of new genotype-speciﬁc treat-
ment guidelines led to cost-savings when compared to IFN  RBV. CONCLUSIONS: 
PegIFN  RBV should be cost-effective compared to other established treatments in 
CHC. The EF approach should be feasible for HTAs in the CHC area. However, 
several issues remain to be solved and the conclusions derived from HTAs based on 
IQWiG’s framework may substantially differ from HTAs assuming uniform willing-
ness-to-pay thresholds across the entire health care system.
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OBJECTIVES: To get insight in what criteria as presented in HTA studies are impor-
tant for decision makers in health care priority setting. METHODS: We performed a 
